Q-omics provides the consensus-scored ALX4 profile across patient tissues and cancer cell-line models. ALX4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ALX4 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ALX4 RNA expression shows 15,448 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where ALX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALX4 survival associations across molecular data types. ALX4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALX4 RNA expression–survival associations across cancer types. High ALX4 expression shows unfavorable associations in HNSC, KIRP, ACC, COAD and LIHC, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ALX4 RNA expression.
This table summarizes ALX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ALX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALX4 shows lower tumor expression in KICH, BRCA, KIRC, THCA and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher ALX4 RNA expression in normal versus tumor tissue (log2 FC = −0.293, t-test p = .006).
This table shows molecular features associated with ALX4 in patient tissues and cancer cell lines. In patient samples, ALX4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
